Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs w… Read more
Rapport Therapeutics, Inc. Common Stock (RAPP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.034x
Based on the latest financial reports, Rapport Therapeutics, Inc. Common Stock (RAPP) has a cash flow conversion efficiency ratio of -0.034x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.46 Million) by net assets ($511.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rapport Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Rapport Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rapport Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rapport Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NorthWest Healthcare Properties Real Estate Investment Trust
TO:NWH-UN
|
0.008x |
|
Beijing eGOVA
SHE:300075
|
-0.006x |
|
OC Oerlikon Corporation AG
OTCGREY:OERLF
|
-0.043x |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
0.016x |
|
Central Securities Corporation
NYSE MKT:CET
|
0.010x |
|
Nongshim
KO:004370
|
0.025x |
|
Strait Innovation Internet Co Ltd
SHE:300300
|
-0.181x |
|
Rithm Property Trust Inc.
OTCGREY:RPTCV
|
N/A |
Annual Cash Flow Conversion Efficiency for Rapport Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Rapport Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $305.43 Million | $-64.83 Million | -0.212x | -120.02% |
| 2023-12-31 | $-25.63 Million | $-27.18 Million | 1.060x | +737.94% |
| 2022-12-31 | $19.50 Million | $-3.24 Million | -0.166x | -- |